CN101466691B - 作为组ⅰ代谢型受体拮抗剂的取代的甲酰胺类化合物 - Google Patents

作为组ⅰ代谢型受体拮抗剂的取代的甲酰胺类化合物 Download PDF

Info

Publication number
CN101466691B
CN101466691B CN2007800211890A CN200780021189A CN101466691B CN 101466691 B CN101466691 B CN 101466691B CN 2007800211890 A CN2007800211890 A CN 2007800211890A CN 200780021189 A CN200780021189 A CN 200780021189A CN 101466691 B CN101466691 B CN 101466691B
Authority
CN
China
Prior art keywords
formula
preparation
mmol
compound
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800211890A
Other languages
English (en)
Chinese (zh)
Other versions
CN101466691A (zh
Inventor
R·T·贝可尔
M·J·菲舍尔
S·L·库克利什
S·P·霍林斯黑德
E·C·R·史密斯
K·塔克乌奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN101466691A publication Critical patent/CN101466691A/zh
Application granted granted Critical
Publication of CN101466691B publication Critical patent/CN101466691B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2007800211890A 2006-06-08 2007-06-07 作为组ⅰ代谢型受体拮抗剂的取代的甲酰胺类化合物 Expired - Fee Related CN101466691B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81183906P 2006-06-08 2006-06-08
US60/811,839 2006-06-08
PCT/US2007/070572 WO2008103185A2 (en) 2006-06-08 2007-06-07 Substituted carboxamides as group i metabotropic receptor antagonists

Publications (2)

Publication Number Publication Date
CN101466691A CN101466691A (zh) 2009-06-24
CN101466691B true CN101466691B (zh) 2011-07-27

Family

ID=39673278

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800211890A Expired - Fee Related CN101466691B (zh) 2006-06-08 2007-06-07 作为组ⅰ代谢型受体拮抗剂的取代的甲酰胺类化合物

Country Status (30)

Country Link
US (1) US7960419B2 (enExample)
EP (1) EP2076502B1 (enExample)
JP (1) JP5108878B2 (enExample)
KR (1) KR101051559B1 (enExample)
CN (1) CN101466691B (enExample)
AT (1) ATE509921T1 (enExample)
AU (1) AU2007347428B2 (enExample)
BR (1) BRPI0712862A2 (enExample)
CA (1) CA2652074C (enExample)
CR (1) CR10410A (enExample)
CY (1) CY1111588T1 (enExample)
DK (1) DK2076502T3 (enExample)
EA (1) EA014233B1 (enExample)
EC (1) ECSP088939A (enExample)
ES (1) ES2362949T3 (enExample)
HR (1) HRP20110436T1 (enExample)
IL (1) IL195632A (enExample)
MA (1) MA30620B1 (enExample)
MX (1) MX2008015485A (enExample)
MY (1) MY148084A (enExample)
NO (1) NO341474B1 (enExample)
NZ (1) NZ573352A (enExample)
PL (1) PL2076502T3 (enExample)
PT (1) PT2076502E (enExample)
RS (1) RS51818B (enExample)
SI (1) SI2076502T1 (enExample)
TN (1) TNSN08506A1 (enExample)
UA (1) UA95480C2 (enExample)
WO (1) WO2008103185A2 (enExample)
ZA (1) ZA200809111B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0804685D0 (en) 2008-03-13 2008-04-16 Univ Edinburgh Therapeutic compounds and their use
MX2010010781A (es) 2008-04-04 2010-12-14 Lilly Co Eli 3-indazolil-4-piridilisotiazoles.
EP2443113A1 (en) * 2009-06-15 2012-04-25 The University Of Edinburgh Amido-isothiazole compounds and their use as inhibitors of 11beta-hsd1 for the treatment of metabolic syndrome and related disorders
JP5779181B2 (ja) 2009-09-16 2015-09-16 ザ ユニバーシティ オブ エディンバラ （４−フェニル−ピペリジン−１−イル）−［５−（１ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン化合物及びそれらの使用
EP2563780B1 (en) 2010-04-29 2015-05-06 The University Of Edinburgh 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1
DK2921489T3 (en) 2012-11-13 2017-10-16 Nissan Chemical Ind Ltd 2-pyridone-RELATED
AU2017329677A1 (en) 2016-09-23 2019-04-18 Bayer Aktiengesellschaft N 3 -cyclically substituted thienouraciles and use thereof
CN117567266B (zh) * 2023-11-07 2024-06-14 康龙化成手性医药技术(宁波)有限公司 一种制备2-甲基环丙羧酸的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0129407A2 (en) * 1983-06-20 1984-12-27 Eli Lilly And Company Improvements in and relating to (3-aryl-5-isothiazolyl)ureas
CN1202162A (zh) * 1995-11-14 1998-12-16 拜尔公司 具有杀虫性能的酰化5－氨基异噻唑、中间产物及其制法
CN1984899A (zh) * 2004-05-12 2007-06-20 先灵公司 Cxcr1和cxcr2趋化因子拮抗剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4328425A1 (de) 1993-08-24 1995-03-02 Basf Ag Acylamino-substituierte Isoxazol- bzw. Isothiazolderivate, Verfahren zu deren Herstellung und ihre Verwendung
DK124393D0 (da) 1993-11-03 1993-11-03 Lundbeck & Co As H Compounds
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
JP3411262B2 (ja) * 1999-08-20 2003-05-26 萬有製薬株式会社 新規スピロ化合物
JP2005501073A (ja) * 2001-08-06 2005-01-13 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害薬活性を有するアミノイソオキサゾール誘導体
EP1667983A4 (en) * 2003-09-23 2010-07-21 Merck Sharp & Dohme PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
BRPI0515571A (pt) * 2004-09-23 2008-07-29 Pfizer Prod Inc agonistas de receptor de trombopoetina

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0129407A2 (en) * 1983-06-20 1984-12-27 Eli Lilly And Company Improvements in and relating to (3-aryl-5-isothiazolyl)ureas
CN1202162A (zh) * 1995-11-14 1998-12-16 拜尔公司 具有杀虫性能的酰化5－氨基异噻唑、中间产物及其制法
CN1984899A (zh) * 2004-05-12 2007-06-20 先灵公司 Cxcr1和cxcr2趋化因子拮抗剂

Also Published As

Publication number Publication date
EP2076502A2 (en) 2009-07-08
JP2009539874A (ja) 2009-11-19
MY148084A (en) 2013-02-28
CA2652074A1 (en) 2008-08-28
MX2008015485A (es) 2009-03-06
EA014233B1 (ru) 2010-10-29
PT2076502E (pt) 2011-06-07
RS51818B (sr) 2011-12-31
SI2076502T1 (sl) 2011-09-30
DK2076502T3 (da) 2011-07-25
KR101051559B1 (ko) 2011-07-22
ECSP088939A (es) 2009-01-30
IL195632A0 (en) 2009-09-01
TNSN08506A1 (en) 2010-04-14
HRP20110436T1 (hr) 2011-08-31
CR10410A (es) 2008-11-28
US20090182025A1 (en) 2009-07-16
EA200870516A1 (ru) 2009-06-30
NO341474B1 (no) 2017-11-27
AU2007347428A1 (en) 2008-08-28
CN101466691A (zh) 2009-06-24
EP2076502B1 (en) 2011-05-18
JP5108878B2 (ja) 2012-12-26
ES2362949T3 (es) 2011-07-15
WO2008103185A2 (en) 2008-08-28
PL2076502T3 (pl) 2011-09-30
WO2008103185A3 (en) 2008-10-30
ATE509921T1 (de) 2011-06-15
ZA200809111B (en) 2009-12-30
CY1111588T1 (el) 2015-10-07
NO20085028L (no) 2008-12-02
IL195632A (en) 2013-11-28
AU2007347428B2 (en) 2012-02-09
HK1131984A1 (en) 2010-02-12
CA2652074C (en) 2013-08-06
BRPI0712862A2 (pt) 2012-12-18
KR20090008460A (ko) 2009-01-21
US7960419B2 (en) 2011-06-14
UA95480C2 (uk) 2011-08-10
NZ573352A (en) 2011-10-28
MA30620B1 (fr) 2009-08-03

Similar Documents

Publication Publication Date Title
CN101466691B (zh) 作为组ⅰ代谢型受体拮抗剂的取代的甲酰胺类化合物
CN105120860B (zh) 组蛋白脱乙酰酶抑制剂
KR101198057B1 (ko) 신규한 ｎ-(2-아미노-페닐)-아미드 유도체
TWI557110B (zh) 作為５－ｈｔ6拮抗劑的芳基磺醯基吡唑啉羧脒衍生物
JP7368365B2 (ja) Ｐ３００／ｃｂｐ ｈａｔ阻害剤及びそれらの使用の方法
GB2216517A (en) 1-(3-aryl-prop-2-enyl)-4-tricyclyl-piperazines
KR20050013255A (ko) 트리시클릭 스테로이드 호르몬 핵 수용체 조절제
SK126695A3 (en) Amino(thio)ether derivative, preparing method and pharmaceutical composition containing its
TW200940533A (en) Amine and ether compounds which modulate the CB2 receptor
MX2014012992A (es) Derivado de quinazolindiona.
MX2013001202A (es) Compuestos de piridina de anillo fusionado.
TW200946117A (en) Compounds having NPY Y5 receptor antagonistic activity
WO2025247412A1 (zh) 一种苯基噻唑胺类PI4KIII β/HDAC双靶抑制剂、制备方法及其药物组合物和应用
WO2021228215A1 (zh) 可用作RORγ调节剂的联芳基类化合物
AU2012384456A1 (en) Novel cholecystokinin receptor ligands
DE60000790T2 (de) [(2-substituierte-5-[3-thienyl)-benzyl]-[2-([2-isopropoxy-5-fluoro]-phenoxy)-ethyl]-amine, verfahren zu ihrer herstellung und ihre verwendung als medikamente
WO2015163604A1 (ko) 옥사졸리딘계 화합물 및 이를 포함하는 선택적 안드로겐 수용체 효능제
TW202440081A (zh) σ-1受體拮抗劑及其應用
HK1131984B (en) Substituted carboxamides as group i metabotropic receptor antagonists
UA82518C2 (uk) Сполуки азетидину, спосіб їх одержання (варіанти), фармацевтична композиція на їх основі
WO2024137968A1 (en) Androgen receptor modulators and methods for their use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110727

Termination date: 20170607

CF01 Termination of patent right due to non-payment of annual fee